Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
August 23 2021 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced the
election of Yujiro S. Hata, to its Board of Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210823005010/en/
Yujiro S. Hata, Board of Directors,
Enanta Pharmaceuticals (Photo: Business Wire)
“We are thrilled to welcome Yujiro Hata to our Board of
Directors,” said Jay R. Luly, Ph.D., President and Chief Executive
Officer of Enanta Pharmaceuticals. “His depth of expertise in
business and corporate development, as well as his experience as a
senior executive and an independent director of several public and
private biotechnology companies, will bring complementary depth to
our Board. Yujiro’s insights will be particularly valuable as we
continue to explore combination therapies to advance our clinical
pipeline in key therapeutic areas.”
“I am delighted to join Enanta as a member of its Board of
Directors. Enanta’s proven, chemistry-driven approach to creating
best-in-class small molecule drugs has allowed the company to
develop a strong, differentiated portfolio of product candidates
across virology and liver disease areas,” commented Mr. Hata. “I
look forward to working with the team, especially in the upcoming
year, when the combination of clinical data readouts in respiratory
syncytial virus, hepatitis B virus, SARS-CoV-2 and non-alcoholic
steatohepatitis has the potential to be truly transformative.”
Mr. Hata has more than 20 years of experience building companies
that have developed innovative therapies. He currently serves as
the Founder and CEO of IDEAYA Biosciences, an oncology-focused
precision medicine company, which he founded in 2015. Under his
leadership, IDEAYA formed a global partnership with GlaxoSmithKline
to develop programs in synthetic lethality, an emerging field in
oncology. From 2015 to 2018, Mr. Hata served as an
Executive-in-Residence at 5AM Ventures. From 2014 to August 2015,
he was Chief Operating Officer at Flexus Biosciences where he
helped lead the company through its acquisition by Bristol-Myers
Squibb in April 2015, and then he served as Chief Operating Officer
at RAPT Therapeutics (formerly FLX Bio). Before then, Mr. Hata held
roles of increasing responsibility, most recently as Vice
President, Corporate Development and Strategy, at Onyx
Pharmaceuticals, when the company achieved approvals of KYPROLIS®
and STIVARGA®, leading to its acquisition by Amgen in October 2013.
Previously Mr. Hata held business development roles at Enanta and
at ImClone Systems, now a subsidiary of Eli Lilly and Company.
Mr. Hata serves on the Boards of Directors of Xencor and
Expansion Therapeutics and is a Board Member of the Moores Cancer
Center at the University of California, San Diego. He obtained his
M.B.A. from the University of Pennsylvania, his B.A. in Chemistry
from Colorado College, and participated in undergraduate studies in
Chemistry and Biology at Oxford University.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), hepatitis B virus
(HBV), non-alcoholic steatohepatitis (NASH) and SARS-CoV-2
(COVID-19). Enanta is also conducting research in human
metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210823005010/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024